Palonosetron Hospira

RSS
Withdrawn

This medicine's authorisation has been withdrawn

palonosetron
MedicineHumanWithdrawn
  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 8 April 2019, the marketing authorisation of Palonosetron Hospira (palonosetron) ceased to be valid in the European Union (EU). The cessation of validity is due to the fact that the marketing authorisation holder, Pfizer Europe MA EEIG, had not marketed Palonosetron Hospira in the EU since its initial marketing authorisation. In accordance with provisions of the sunset clause1, the marketing authorisation of the medicinal product lapsed as the product had not been marketed in any of the EU Member States within three years of its initial authorisation. 

Pfizer Europe MA EEIG confirmed that the product had not been marketed due to commercial reasons. Palonosetron Hospira was granted marketing authorisation in the EU on 8 April 2016 for prevention of nausea and vomiting associated with cancer chemotherapy. The marketing authorisation was initially valid for a 5-year period. 

Palonosetron Hospira is a generic medicine of Aloxi. There are other generic medicinal products of Aloxi authorised and marketed in the EU. 

The European Public Assessment Report (EPAR) for Palonosetron Hospira is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (714.67 KB - PDF)

View

español (ES) (645.44 KB - PDF)

View

čeština (CS) (700.5 KB - PDF)

View

dansk (DA) (644.77 KB - PDF)

View

Deutsch (DE) (646.19 KB - PDF)

View

eesti keel (ET) (644.04 KB - PDF)

View

ελληνικά (EL) (742.46 KB - PDF)

View

français (FR) (645.76 KB - PDF)

View

hrvatski (HR) (663.3 KB - PDF)

View

italiano (IT) (644.63 KB - PDF)

View

latviešu valoda (LV) (699.31 KB - PDF)

View

lietuvių kalba (LT) (666.63 KB - PDF)

View

magyar (HU) (694.79 KB - PDF)

View

Malti (MT) (699.89 KB - PDF)

View

Nederlands (NL) (645.57 KB - PDF)

View

polski (PL) (700.96 KB - PDF)

View

português (PT) (645.19 KB - PDF)

View

română (RO) (665.85 KB - PDF)

View

slovenčina (SK) (699.65 KB - PDF)

View

slovenščina (SL) (693.45 KB - PDF)

View

Suomi (FI) (644.45 KB - PDF)

View

svenska (SV) (645.24 KB - PDF)

View

Product information

български (BG) (225.56 KB - PDF)

View

español (ES) (796.73 KB - PDF)

View

čeština (CS) (1.21 MB - PDF)

View

dansk (DA) (791.76 KB - PDF)

View

Deutsch (DE) (801.91 KB - PDF)

View

eesti keel (ET) (781.47 KB - PDF)

View

ελληνικά (EL) (1.48 MB - PDF)

View

français (FR) (803.48 KB - PDF)

View

hrvatski (HR) (798.68 KB - PDF)

View

íslenska (IS) (797.16 KB - PDF)

View

italiano (IT) (788.09 KB - PDF)

View

latviešu valoda (LV) (1.23 MB - PDF)

View

lietuvių kalba (LT) (799.33 KB - PDF)

View

magyar (HU) (1.24 MB - PDF)

View

Malti (MT) (1.29 MB - PDF)

View

Nederlands (NL) (794.44 KB - PDF)

View

norsk (NO) (786.4 KB - PDF)

View

polski (PL) (1.24 MB - PDF)

View

português (PT) (797.82 KB - PDF)

View

română (RO) (793.56 KB - PDF)

View

slovenčina (SK) (1.2 MB - PDF)

View

slovenščina (SL) (1.25 MB - PDF)

View

Suomi (FI) (787.3 KB - PDF)

View

svenska (SV) (787.3 KB - PDF)

View
Latest procedure affecting product information: IAIN/0005/G
12/12/2018
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (640.77 KB - PDF)

View

español (ES) (578.37 KB - PDF)

View

čeština (CS) (620.16 KB - PDF)

View

dansk (DA) (600.91 KB - PDF)

View

Deutsch (DE) (578.03 KB - PDF)

View

eesti keel (ET) (583.91 KB - PDF)

View

ελληνικά (EL) (629.34 KB - PDF)

View

français (FR) (578.15 KB - PDF)

View

hrvatski (HR) (658.15 KB - PDF)

View

italiano (IT) (578.23 KB - PDF)

View

latviešu valoda (LV) (622.5 KB - PDF)

View

lietuvių kalba (LT) (611.18 KB - PDF)

View

magyar (HU) (605.35 KB - PDF)

View

Malti (MT) (628.27 KB - PDF)

View

Nederlands (NL) (586.98 KB - PDF)

View

polski (PL) (620.45 KB - PDF)

View

português (PT) (578.05 KB - PDF)

View

română (RO) (603.33 KB - PDF)

View

slovenčina (SK) (619.58 KB - PDF)

View

slovenščina (SL) (629.74 KB - PDF)

View

Suomi (FI) (581.51 KB - PDF)

View

svenska (SV) (586.64 KB - PDF)

View

Product details

Name of medicine
Palonosetron Hospira
Active substance
palonosetron hydrochloride
International non-proprietary name (INN) or common name
palonosetron
Therapeutic area (MeSH)
  • Nausea
  • Vomiting
  • Cancer
Anatomical therapeutic chemical (ATC) code
A04AA05

Pharmacotherapeutic group

Antiemetics and antinauseants

Therapeutic indication

Palonosetron Hospira is indicated in adults for:

  • the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy;
  • the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Palonosetron Hospira is indicated in paediatric patients 1 month of age and older for:

  • the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Authorisation details

EMA product number
EMEA/H/C/004069

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Marketing authorisation holder
Pfizer Europe MA EEIG

Boulevard de la Plaine 17
1050 Bruxelles
Belgium

Marketing authorisation issued
08/04/2016
Revision
4

Assessment history

This page was last updated on

Share this page